Bausch + Lomb Corp

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bausch + Lomb Corp reports stellar Q2 performance and raises guidance

Bausch + Lomb Corp's Q2 2024 earnings call showcased robust performance, with revenue growth, margin improvement, and raised guidance reflecting a strong outlook.
The company's emphasis on innovation, operational excellence, and long-term growth strategies highlights a commitment to sustained success and shareholder value.
While facing challenges in specific areas and competitive markets, Bausch + Lomb's focus on balancing growth, margins, and investments positions it well for future opportunities.

Bausch + Lomb Corp (BLCO) reports strong Q3 earnings and raises full-year guidance amidst strategic growth focus

Bausch + Lomb Corp (BLCO) delivered a strong Q3 performance with revenue growth, margin expansion, and raised full-year guidance, reflecting a solid financial outlook.
The company's focus on execution, product launches, and strategic investments is driving growth and profitability across segments, showcasing a resilient business strategy.
While challenges like market dynamics and operational complexities persist, opportunities in market expansion, innovation, and strategic partnerships offer avenues for sustained growth.
Overall, Bausch + Lomb Corp (BLCO) is well-positioned for continued success through its commitment to growth, innovation, and operational excellence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brent Saunders led Bausch + Lomb Corporation when it was sold to Valeant Pharmaceuticals. He later led and sold competitor Allergan to AbbVie.

Bausch + Lomb: Brent Saunders Return Bodes Well For Shareholders

Bausch + Lomb Corporation (NYSE:BLCO ) Q4 2022 Earnings Conference Call February 22, 2023 8:00 AM ET Company Participants Art Shannon – Investor Relations Joe Papa – Chief Executive Officer Brent Saunders – Incoming Chief Executive Officer and Chairman of the Board of Directors Sam Eldessouky – Executive Vice President and Chief Financial Officer Conference Call Participants Craig Bijou – Bank of America Cecilia Furlong – Morgan Stanley Matt Miksic – Barclays Vijay Kumar – Evercore ISI Joanne Wuensch – Citi Operator Good morning, and welcome to Bausch + Lomb's Fourth Quarter 2022 Earnings Call. All participants will be in a listen-only mode.

Bausch + Lomb Corporation (BLCO) Q4 2022 Earnings Call Transcript

Bausch Health Companies Inc

Bausch + Lomb Corp. BLCO, -2.01% said Wednesday it had a loss of $1 million, or breakeven on a per-share basis, for the fourth quarter, after earnings of $51 million, or 15 cents a share, in the year-earlier period. The company, which went public in May when it was spun out of Bausch Health, said adjusted per-share earnings came to 23 cents, a penny ahead of the 22 cent FactSet consensus.

Bausch + Lomb beats Q4 profit and revenue estimates

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2022 financial results. “Bausch + Lomb delivered another year of strong performance in 2022, growing the business organically1,2 at a mid-single-digit rate.

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results

Bausch + Lomb Corp.'s decision to bring back Brent Saunders as CEO hints at the company's broader ambitions in the global eye-care market.

After IPO, Bausch + Lomb turns to an industry favorite to run the company

Bausch + Lomb Corp. BLCO, +1.31% said Wednesday it has named Brent Saunders as chief executive and chair effective March 6. Saunders, who will return to the company he headed from 2010 to 2013, will replace Joseph Papa, who is stepping down.

Bausch + Lomb names ex-CEO Brent Saunders as CEO, replacing Joseph Papa

Campaign to Feature Personal Stories and Images from Bausch + Lomb SightMatters Community Members During Age-Related Macular Degeneration Month

New Bausch + Lomb Social Media Campaign Highlights What ‘Sights' Inspire AMD Patients

VAUGHAN, Ontario & TAMPERE, Finland--( BUSINESS WIRE )--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Modulight Corporation (“Modulight”), a biomedical laser company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb's VISUDYNE® (verteporfin for injection) photodynamic therapy (PDT) for the treatment of patients with predominantly classic subfoveal choroidal neovascularization, or the creation of abnormal choroidal blood vessels, due to Age-related Macular Degeneration (AMD).1 ML6710i is expected to be available for eye care professionals during the first half of 2023.

Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb's VISUDYNE® (Verteporfin for Injection)

Bausch + Lomb has had a rocky time over the past few quarters, with sales coming under pressure and margins contracting. Most of the issues, though, seem transitory in nature and the firm is likely to see some improvement moving forward even though some issues might be longer lasting.

Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect

VAUGHAN, Ontario--( BUSINESS WIRE )--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2022 financial results on Wednesday, Feb. 22, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22

VAUGHAN, Ontario--( BUSINESS WIRE )--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of PreserVision® AREDS 2 Formula mini soft gels with OCUSorb™. This product is the only AREDS 2 eye vitamin with the OCUSorb formulation. Offering a proprietary composition of lutein and zeaxanthin, OCUSorb has been clinically shown to provide superior absorption of these nutrients into the body as compared to the original PreserVision AREDS 2 mini soft gel formula.†1*

Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

VAUGHAN, Ontario--( BUSINESS WIRE )--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, has published a company update presentation designed to complement remarks that will be provided by management at 3:00 p.m. PT (6:00 p.m. ET) today, Jan. 9, 2023, during the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation provides an overview of the Company's recent performance and achievements, and offers insight into future goals and catalysts for 2023 and beyond.

Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference

VAUGHAN, Ontario--( BUSINESS WIRE )--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that Joseph C. Papa, chief executive officer, and Sam Eldessouky, executive vice president and chief financial officer, are scheduled to participate at the 41st Annual J.P. Morgan Healthcare Conference on Jan. 9, 2023, at 3:00 p.m. PT (6:00 p.m. ET).

Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference

VAUGHAN, Ontario & HEIDELBERG, Germany--( BUSINESS WIRE )--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in class ocular therapeutics, today announced that Ophthalmology, the peer-reviewed journal of the American Academy of Ophthalmology, has published results from the pivotal Phase 3 trial GOBI, which is one of two pivotal Phase 3 trials for NOV03 (perfluorohexyloctane). NOV03 is being investigated to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). The U.S. Food and Drug Administration (FDA) assigned NOV03 a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2023.

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

VAUGHAN, Ontario--( BUSINESS WIRE )--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national non-profit organization with the vision of curing glaucoma, today announced the U.S. launch of ‘Screen, Protect, Cure,' a campaign designed to provide educational resources and raise awareness of glaucoma, a leading cause of irreversible blindness, during Glaucoma Awareness Month.1

Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month

VAUGHAN, ON , Dec. 22, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced that the Company and its CEO, Joseph C. Papa,  have entered into an Amended and Restated Separation Agreement (the "Amended Separation Agreement"), pursuant to which Mr.

Bausch + Lomb Amends CEO Separation Agreement

Provides Lenses Up to Eight Hours of Moisture* VAUGHAN, ON , Dec. 13, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free multi-dose rehydrating drop for use with soft and rigid gas permeable contact lenses.  "We are proud to continue to build upon our successful Biotrue brand with the FDA clearance of Biotrue Hydration Boost for Contacts," said Joe Gordon, president, Global Consumer, Vision Care and Surgical, Bausch + Lomb.

Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops

VAUGHAN, ON , Dec. 12, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced its first-of-its-kind ONE by ONE and Biotrue Eye Care Recycling programs have been named a gold winner in the Most Environmentally Friendly Service of the Year category by the 2022 Best in Biz Awards. "For the past two years, our ONE by ONE contact lens recycling program has received gold for 'Most Environmentally Friendly Service of the Year' from the Best in Biz Awards.

Bausch + Lomb's ONE by ONE and Biotrue® Eye Care Recycling Programs Win Gold for Most Environmentally Friendly Service of the Year from Best in Biz Awards

VAUGHAN, ON , Nov. 29, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced its latest contact lens solution, Biotrue Hydration Plus, has received Business Intelligence Group's (BIG) 2022 BIG Awards for Business Product of the Year award. "Biotrue Hydration Plus was built upon our successful Biotrue Multi-Purpose Solution to provide contact lens wearers a solution that delivers even more moisture to their contact lenses - potentially a full day's worth of wear,"* said Joe Gordon, president, Global Consumer, Surgical and Vision Care, Bausch + Lomb.

Bausch + Lomb's Biotrue® Hydration Plus Multi-Purpose Solution Receives Product of the Year Award from Business Intelligence Group's 2022 BIG Awards for Business

VAUGHAN, ON , Nov. 15, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today, on America Recycles Day, announced its unique ONE by ONE and Biotrue Eye Care Recycling programs have collected a total of 58,677,480 million units, or 356,723 pounds, of used contact lens, eye care and lens care materials, which is equivalent to the weight of 108 midsize vehicles1. The first-of-its-kind programs are made possible through a collaboration with TerraCycle®, a world leader in the collection and repurposing of hard-to-recycle post-consumer waste.

Bausch + Lomb Reports More Than 58 Million Units of Contact Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Over the long term, its geographic mix of over 100 countries is a strength, but near term, the strength of the U.S. dollar is weighing on its performance. Strong brands and pricing power support the company under the weak economic environment.

Bausch + Lomb: A Solid Play In Challenging Economic Times

VAUGHAN, ON , Nov. 7, 2022 /PRNewswire/ -- Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that Joseph C. Papa, chief executive officer, and Sam Eldessouky, executive vice president and chief financial officer are scheduled to participate at the 5th Annual Evercore ISI HealthCONx Conference on Nov. 30, 2022, at 9:40 a.m.

Bausch + Lomb Announces Participation at the 5th Annual Evercore ISI HealthCONx Conference

Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Alison Ryan - Investor Relations Joseph Papa - Chief Executive Officer Sam Eldessouky - Executive Vice President and Chief Financial Officer Conference Call Participants Zack Weiner - Jefferies Cecilia Furlong - Morgan Stanley Vijay Kumar - Evercore Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Operator Good morning, and welcome to the Bausch + Lomb Third Quarter 2022 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

Bausch + Lomb Corporation (BLCO) Q3 2022 Earnings Call Transcript

Bausch & Lomb Corp. BLCO, +0.63% said Wednesday that it had a loss of $18 million, or 5 cents per share, in the first quarter of 2022, after a gain of $60 million, or 17 cents per share, in the same quarter a year ago. Adjusted earnings per share were 31 cents, against a FactSet consensus of 23 cents.

Bausch + Lomb beats earnings expectations in Q3

Third-Quarter 2022 Financial Results Revenues of $942 Million GAAP Net Loss Attributable to Bausch + Lomb Corporation of $18 Million Adjusted EBITDA (non-GAAP) 1  of $187 Million GAAP Cash Flow from Operations of $27 Million and $186 Million in the Third Quarter and Year-To-Date, Respectively Third-Quarter Reported Revenues Declined 1%, and Organic Revenues1, 2  Grew 5%, Driven by Growth Across All Segments Foreign Exchange Negatively Impacted Revenues by $55 Million in the Third Quarter Revised 2022 Full-Year Revenue and Adjusted EBITDA (non-GAAP)1 Guidance Ranges 3 , Primarily Due to Currency Headwinds VAUGHAN, ON , Nov. 2, 2022 /PRNewswire/ -- Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2022 financial results. "Our underlying robust business growth across all three segments enabled us to largely offset inflationary and currency headwinds and deliver strong third-quarter results," said Joseph C.

News for Bausch + Lomb Corp Stock (BLCO)